Topical Statins Show Promise in Treating Rare Genetic Skin Disease DSAP

A new systematic review supports the use of topical statins for treating disseminated superficial actinic porokeratosis (DSAP), a rare but serious genetic skin disease. The findings, published in Clinical and Experimental Dermatology, highlight the potential of statins as a targeted therapy for this progressive condition.

Palvella Therapeutics has announced plans to advance its QTORINTM pitavastatin into Phase 2 trials by late 2026, aiming to provide the first FDA-approved treatment for DSAP patients.

Porokeratosis is a chronic skin disorder characterised by abnormal lesions that can become malignant, particularly in DSAP cases. The disease is driven by mutations in the mevalonate pathway, which statins—commonly used for cholesterol management—may help regulate. Early studies suggest that topical statin application can reduce lesion size and ease symptoms, though evidence remains limited.

The recent review consolidates findings from multiple studies on off-label statin use in porokeratosis. While results show partial clinical benefits, researchers stress the need for controlled trials to confirm safety and effectiveness. Palvella's QTORINTM pitavastatin, a topical formulation, is designed specifically for DSAP, addressing a gap where no approved treatments currently exist.

Beyond DSAP, Palvella is also developing QTORINTM rapamycin for other rare skin and vascular conditions, including microcystic lymphatic malformations and angiokeratomas. The company focuses on diseases with high unmet medical needs, aiming to bring novel therapies to patients who lack effective options.

The review reinforces the potential of topical statins in managing porokeratosis, though further research is required. Palvella's upcoming Phase 2 trial for QTORINTM pitavastatin could mark a significant step toward an approved DSAP treatment. If successful, it may offer patients a much-needed alternative to off-label therapies.